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Abstract
Background: Preterm birth accounting approximate 10% of pregnancies in women is a tremendous social, clinical and
economic burden. However, its underlying causes remain largely unknown. Emerging evidence suggests that
endocannabinoid signaling via cannabinoid receptor CB1 play critical roles in multiple early pregnancy events in both
animals and humans. Since our previous studies demonstrated that loss of CB1 defers the normal implantation window in
mice, we surmised that CB1 deficiency would influence parturition events.
Methods and Findings: Exploiting mouse models with targeted deletion of Cnr1, Cnr2 and Ptgs1 encoding CB1, CB2 and
cyclooxygenase-1, respectively, we examined consequences of CB1 or CB2 silencing on the onset of parturition. We
observed that genetic or pharmacological inactivation of CB1, but not CB2, induced preterm labor in mice.
Radioimmunoassay analysis of circulating levels of ovarian steroid hormones revealed that premature birth resulting
from CB1 inactivation is correlated with altered progesterone/estrogen ratios prior to parturition. More strikingly, the
phenotypic defects of prolonged pregnancy length and parturition failure in mice missing Ptgs1 were corrected by
introducing CB1 deficiency into Ptgs1 null mice. In addition, loss of CB1 resulted in aberrant secretions of corticotrophin-
releasing hormone and corticosterone during late gestation. The pathophysiological significance of this altered
corticotrophin-releasing hormone-driven endocrine activity in the absence of CB1 was evident from our subsequent
findings that a selective corticotrophin-releasing hormone antagonist was able to restore the normal parturition timing in
Cnr1 deficient mice. In contrast, wild-type females receiving excessive levels of corticosterone induced preterm birth.
Conclusions: CB1 deficiency altering normal progesterone and estrogen levels induces preterm birth in mice. This defect is
independent of prostaglandins produced by cyclooxygenase-1. Moreover, CB1 inactivation resulted in aberrant
corticotrophin-releasing hormone and corticosterone activities prior to parturition, suggesting that CB1 regulates labor
by interacting with the corticotrophin-releasing hormone-driven endocrine axis.
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Introduction
Anandamide and 2-arachidonoylglycerol are two major en-
docannabinoids that activate two G protein-coupled cannabinoid
receptors CB1 and CB2, encoded by Cnr1 and Cnr2, respectively
[1–4]. These endocannabinoids mimic many effects of D
9-
tetrahydrocannabinol (THC), a major psychoactive component
of marijuana, on central and peripheral systems [5–10]. With
respect to female reproduction, we first provided evidence in mice
for the presence of CB1 in preimplantation embryos [11,12] and
of anandamide in the oviduct and uterus [12–15], suggesting that
endocannabinoid signaling is operative during early pregnancy.
This was further supported by our findings of biphasic effects of
anandamide on embryo development and implantation [16,17].
For example, anandamide at a low concentration makes the
blastocyst competent for implantation, while at a higher con-
centration it attenuates this response [16]. These observations later
led to studies in humans showing an association of higher
anandamide levels with spontaneous pregnancy loss [18].
Moreover, we recently found that loss of CB1 often derails
oviductal embryo transport, preventing on-time implantation [19].
Since a short delay in on-time implantation adversely affects later
developmental processes [20–22], we explored the consequences
of silencing of CB1 on the onset of labor.
Here we demonstrate that CB1 inactivation in mice induces
preterm labor by altering normal progesterone/estrogen ratios
prior to parturition. This defect is independent of cyclooxygenase-
1 (COX-1)-produced prostaglandins, since loss of CB1 overrides
delayed parturition that occurs in Ptgs-1 deficient mice. More
strikingly, loss of CB1 resulted in altered corticotrophin-releasing
hormone (CRH) and corticosterone (CTS) levels during late
gestation, suggesting that CB1 regulates labor by interacting with
CRH-CTS endocrine axis. This study has high clinical relevance,
since there is evidence that normal onset and duration of labor
involve anandamide signaling in women [23,24] and that CRH is
considered as a pregnancy clock controlling pregnancy length in
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accounting approximate 10% of pregnancies in women is a major
social, clinical and economic burden [27,28].
Results and Discussion
CB1 deficiency induces preterm labor in mice
Increasing evidence points toward critical roles of endocannabi-
noid signaling during early pregnancy [8–10]. We recently
demonstrated that loss of CB1 derails oviductal embryo transport,
leading to deferral of on-time embryo implantation [19]. Since an
initial deferral of implantation is often associated with delayed
parturition [22], we speculated that CB1 deficiency would result in
delayed parturition in mice. However, we observed that genetic loss
of Cnr1, but not Cnr2, leads to preterm labor (Figure 1A).
Consequently, fetal weight at birth in Cnr1
2/2 mice is significantly
reduced compared with wild-type (WT) mice (Figure 1B). In
contrast, the parturition events in mice missing Cnr2 are apparently
normal (Figure 1A & B).These results may explain why Cnr1
2/2
pups display poor suckling activities during early days after birth and
why their weight gain during postnatal development remains
significantly lower than WT control pups [29].
Since Cnr1
2/2 mice display multiples defects during early
pregnancy, including asynchronous preimplantation embryo
development [12], impaired oviductal embryo transport and
deferred implantation [19], it was not clear whether preterm birth
in Cnr1
2/2 mice was seeded during early pregnancy or resulted
from CB1 deficiency during the late gestational period. Therefore,
we next examined the consequences of silencing cannabinoid
signaling in WT mice by subcutaneous administration of selective
CB antagonists during late gestation. As illustrated in Figure 1C
&D , similar preterm parturition occurred in WT mice receiving a
CB1-selective antagonist SR141716 (SR1) [30], but not a CB2-
selective antagonist SR144528 (SR2) [31], on days 14–18 of
pregnancy. These observations suggest that endocannabinoid
signaling via CB1 is critical to normal gestational length.
The initiation of parturition results from a synchronous
interplay of both maternal and fetal factors [28]. Thus, we
assessed the contribution of maternal versus embryonic CB1 to
parturition defects in Cnr1
2/2 mice by mating null females with
Figure 1. Genetic or pharmacological silencing of CB1 induces preterm labor. (A&B ) Mice missing Cnr1, but not Cnr2, show early onset of
labor with reduced fetal weights at birth. (C&D ) Preterm labor occurs in wild-type (WT) pregnant mice receiving a CB1-selective antagonist
SR141716 (SR1), but not a CB2-selective antagonist SR144528 (SR2), on days 14–18 with little effects on fetal weights. Numbers within bars indicate
the number of mice examined in panels A and C. The average fetal weights (mg) at birth are shown in panels B and D. The bars with different letters
are significantly different (P,0.01).
doi:10.1371/journal.pone.0003320.g001
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observed that preterm labor phenotype was sustained in pregnant
Cnr1
2/2 females bearing heterozygous embryos, although birth
weights of heterozygous pups were comparable to those of wild-
type pups at birth (Figure S1A & B). The results indicate that
maternal CB1 signaling is critical for timely onset of labor.
CB1 deficiency alters normal progesterone and estrogen
secretions prior to parturition in mice
Recent evidence suggests the involvement of endocannabinoid
signaling via central CB1 in neuroendocrine regulation of
reproduction. For example, both exogenous cannabinoids and
endocannabinoids have been shown to modulate the secretion of
hypothalamicandpituitaryhormonesincludingluteinizinghormone
and prolactin in rodents [32–36]. To reveal potential causes of
preterm birth in the absence of CB1 in mice, we first examined the
expression of CB1 in the hypothalamus and ovary. As illustrated in
Figure 2A & B, we observed a wide distribution of CB1 in these
tissues on day 18 of pregnancy, suggesting the contention that
endocannabinoids would impact the hypothalamic-ovarian axis at
multiple levels during late gestation. Since functional progesterone
(P4) withdrawal either due to fall in circulating P4 levels or
attenuation of P4 action together with heightened estrogen action
determines the parturition timing in most viviparous species
including humans [37], we measured serum levels of P4 and 17b-
estradiol (E2)i nCnr1
2/2 females during late gestation to assess
potential causes of preterm labor in the absence of CB1. As shown in
Figure 3A, CB1 deficiency induced an early drop in serum P4 levels
on day 19 of pregnancy. In contrast, circulating E2 levels
substantially increased on days 16–18 with the loss of CB1
(Figure 3B). This inverse relationship between P4 and E2 levels in
the absence of CB1 creates a significant decrease in P4/E2 ratio
(Figure 3C), leading to preterm birth in Cnr1
2/2 females.
Western blotting analysis of key steroid biosynthetic and
metabolic enzymes demonstrated that while levels of cytochrome
P450 cholesterol side-chain cleavage enzyme and 3b-hydroxyste-
roid dehydrogenase (3b-HSD) were comparable in wild-type and
Cnr1 null ovaries (data not shown), levels of cytochrome P450
aromatase (P450Arom) and 17b-HSD7, which primarily contrib-
ute to ovarian E2 biosynthesis during gestation in mice [38], were
upregulated in Cnr1
2/2 ovaries (Figure 4). Moreover, levels of
20a-HSD, which metabolizes P4 into biologically inactive 20a-
dihydroprogesterone, were substantially increased in Cnr1
2/2
ovaries on day 19 of pregnancy as opposed to that occurs in WT
ovaries on day 20 (Figure 4). These temporal changes in P4
metabolic and estrogen biosynthetic enzymes in null ovaries
correlate well with our finding of early fall in P4 with rising E2
levels preceding early onset of parturition. As shown in Figure
S2A & B, our observation of restoration of normal parturition in
Cnr1
2/2 mice by a subcutaneous injection of P4 (1 mg/mouse) on
day 18 further supports that a decreased P4/E2 ratio is a cause of
preterm labor in null females. With respect to contribution of
gonadotropins and prolactin on this altered ovarian P4 and E2
secretion pattern in the absence of CB1, similar circulating levels
of luteinizing hormone were observed in WT and Cnr1
2/2 mice
on days 14–18 of pregnancy. However, basal levels of follicle
stimulating hormone substantially increased in Cnr1
2/2 mice (data
not shown). Placenta-derived prolactin-like hormones, but not
pituitary prolactin, primarily act to maintain luteal P4 secretion
during late gestation in mice [38,39]. Nonetheless, it would be
Figure 2. Expression of CB1 transcript and protein in the wild-type (WT) brain (A) and ovary (B) on day 18 of pregnancy. Bar, 100 mm.
3V, third ventricle; Arc, arcuate nucleus of the hypothalamus; Cx, cortex; Hip, hippocampus; Subl, subincertal nucleus; VMH, ventromedial
hypothalamic nucleus; CL, corpus luteum; f, follicle; o, oocyte.
doi:10.1371/journal.pone.0003320.g002
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prolactin secretion at various stages of pregnancy.
Loss of CB1 overrides delayed parturition that occurs in
cyclooxygenase-1 deficient mice
In mice, genetic ablation of Ptgs1, encoding cyclooxygenase
(COX)-1, results in delayed or failure of parturition because of
impaired luteolysis with sustained P4 production [40,41]. To
confirm our finding that early decline in serum P4 levels is a trigger
for preterm birth in Cnr1
2/2 mice, we introduced CB1 deficiency
into Ptgs1
2/2 mice to examine their parturition status. It was
exciting to see that the loss of CB1 overrides COX-1 deficiency-
induced delayed parturition (Figure 5A) and remarkably
improves the survival rate of newborn pups (Figure 5B). Similar
observations were also noted in pregnant Ptgs1
2/2 mice receiving
SR1, but not SR2, on days 14–18 (Figure 5C & D). These results
suggest that CB1 signaling has a unique role in regulating normal
parturition that is independent of COX-1-derived prostaglandin
F2a, but CB1 deficiency can correct the effects produced by COX-
1 deficiency. Recent evidence suggests that cyclooxygenases
participate in oxidative metabolism of endocannabinoids, owing
to their structural similarity to polyunsaturated fatty acids. For
example, both anandamide and 2-arachidonoylglycerol can serve
as substrates for COX-2 [42–44], and COX-1 [45] in the context
of cell types and conditions. Moreover, there is evidence that
endocannabinoids via CB1 can upregulate COX-2 expression and
thus prostaglandin E2 production in human gestational mem-
branes during late pregnancy [46]. It remains to be determined
whether COX-1 deficiency induced delayed parturition is
associated with aberrant cannabinoid-CB1 signaling in mice.
CB1 deficiency induces aberrant CRH-driven endocrine
activities leading to preterm labor in mice
Increasing evidence suggests that the endocannabinoid system
influences the secretion of CRH [47,48], which serves as a clock
regulating the length of human pregnancy [25,26]. To further
reveal underlying causes of preterm birth in Cnr1
2/2 mice, we
examined the status of CRH levels during late pregnancy. As
illustrated in Figure 6A, while circulating CRH levels peaked on
day 19 of pregnancy proceeding the day of labor onset in WT
females, an aberrant CRH secretion pattern was noted in mutant
females; the levels showed an early rise on day 14 and thereafter
remained steady through day 20 in Cnr1
2/2 females. This early
rise in CRH levels in peripheral circulation could be due to
dysregulation of the hypothalamus-adrenal axis with an enhanced
circadian drive on this stress-related axis in Cnr1
2/2 mice as
previously demonstrated [49]. In fact, we observed significant
increases in circulating corticosterone (CTS) levels on days 14–16
of pregnancy in mutant females compared with WT females
(Figure 6B). These observations collectively point toward the
concept that CB1 signaling is crucial for maintaining normal
CRH-CTS activities prior to the onset of parturition in mice.
Figure 3. CB1 deficiency alters normal progesterone (P4) and estradiol-17b (E2) levels prior to parturition in mice. Serum P4 and E2
levels were analyzed by radioimmunoassay. While CB1 deficiency induced an early drop in serum P4 levels on day 19 (A), circulating E2 levels were
elevated on days 16–18 (B), resulting in a remarkable decrease in P4/E2 ratio prior to labor in Cnr1
2/2 females (C) (n=6–10, *P,0.05).
doi:10.1371/journal.pone.0003320.g003
Figure 4. Western blot analysis of cytochrome P450 aromatase (P450Arom), 17b-hydroxysteroid dehydrogenase 7 (17b-HSD7) and
20a-HSD in wild-type (WT) and Cnr1
2/2 ovaries during late gestation.
doi:10.1371/journal.pone.0003320.g004
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showed the presence of CRH and its type I receptor (CRH-RI) in
WT day 18 corpora lutea (Figure S3), suggesting potential
interactions of CB1 and CRH signaling within the ovary prior to
parturition. In fact, we noted an early induction of ovarian CRH
expression in Cnr1
2/2 mice with preterm labor (Figure 6C),
further supporting that an altered CRH activity is one cause of
preterm birth in mice missing CB1. Since there is evidence that
CRH interferes with hypothalamic-pituitary-gonadal axis func-
tion by acting directly at the ovarian level [50,51], we speculate
that CB1 deficiency-induced aberrant CRH signaling is a
potential cause of abnormal P4 and E2 secretion in Cnr1
2/2
ovary. However, it is to be noted that while the ovary as the
primary site of P4 synthesis in pregnant mice contributes to CRH
secretion, CRH like P4 is mainly produced by the placenta during
late gestation in humans [47]. Regardless of the site of origin of
CRH in various species, the physiological relevance of CRH-
CTS axis in the onset of normal labor in mice is further
supported by our observations that Antalarmin hydrochloride
(AH), a CRH-RI selective antagonist, restored normal parturition
in Cnr1
2/2 mice with little effects on fetal birth weights when
females were treated on days 15–17 of pregnancy (Figure 7A &
B). In contrast, elevated levels of CTS imposed by exogenous
administration induced preterm birth with reduced fetal weights
in WT females (Figure 7C & D), similar to labor defects in
Cnr1
2/2 mice.
Collectively, we provide here multiple lines of evidence that
signaling via CB1 is crucial for the normal onset of labor; its absence
induces preterm birth via altering ovarian steroid synthesis and
degradation, and CRH-CTS activities. These novel findings have
high clinical relevance, since increases in circulating levels of
anandamide are associated with labor onset and duration in women
[23] and that CRH controlsthe length of human pregnancy [25,26].
This is especially a concern in the light of little change in high
preterm birth rates during the past 30 years [27,28], and the use of a
selective CB1 antagonist in Europe as an anti-obesity drug [52,53].
There is evidence that polymorphism of the Cnr1 gene occurs in
humans [54] and is associated with variable drug dependency [55].
It remains to be seen whether preterm labor in women is associated
with Cnr1 gene polymorphism or mutation.
Figure 5. Loss of CB1 overrides delayed parturition that occurs in Ptgs1
2/2 mice. (A&B ) The onset of parturition and survival rate of
newborn pups in mice missing both Cnr1 and Ptgs1 are substantially improved in contrast to delayed parturition in Ptgs1
2/2 mice. (C&D ) Parturition
defects were largely restored in pregnant Ptgs1
2/2 mice receiving a CB1-selective antagonist SR141716 (SR1), but not a CB2-selective antagonist
SR144528 (SR2), on days 14–18. Numbers within the bars indicate number of mice examined in panels A and C. The bars with different letters are
significantly different (P,0.01).
doi:10.1371/journal.pone.0003320.g005
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Animal models
All experiments were conducted in accordance with National
Institutes of Health guidelines and were approved by the
Intuitional Animal Care and Use Committee. Cnr1, Cnr2 and
Ptgs1 mutant mice on C57BL/6J/129 mixed genetic background
were generated as previously described [41,56,57]. Cnr1
2/2 and
Ptgs1
2/2 mice were cross-bred to generate Cnr1
2/2/Ptgs1
2/2
double null mice. Females were mated with fertile males of the
same strain to induce pregnancy. The presence of a vaginal plug
was considered day 1 of pregnancy. Parturition events were
monitored on days 19–21. The time of parturition was defined as
complete delivery of pups.
Figure 6. Aberrant levels of CRH and corticosterone from CB1 deficiency contribute to preterm birth in mice. (A&B ) Circulating levels
of CRH and corticosterone in pregnant WT and Cnr1
2/2 mice during late gestation (n=4–5, *P,0.05). (C) Western blot analysis of CRH in WT and
Cnr1
2/2 ovaries during late gestation, showing an early induction of ovarian CRH expression in mutant females.
doi:10.1371/journal.pone.0003320.g006
Figure 7. Pharmacological silencing of CRH activities by Antalarmin hydrochloride (AH) on days 15–17 restores normal labor in
Cnr1
2/2 mice with little effects on fetal birth weights (A & B), while enhanced corticosterone (CTS) activity on days 14–18 induces
preterm birth with impaired fetal growth in wild-type (WT) mice (C & D). Numbers within bars indicate the number of mice examined in
panels A and C. The average fetal weights (mg) are shown in panels B and D. The bars with different letters are significantly different (P,0.01).
doi:10.1371/journal.pone.0003320.g007
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To explore the consequences of pharmacological silencing of
CB1 receptors on the onset of parturition, pregnant females
received daily subcutaneous administration of SR141716, a CB1
selective antagonist or SR144528, a CB2 selective antagonist at a
dose of each 10 mg/Kg?BW, respectively on days 14–18 of
pregnancy. To examine the effects of neutralizing CRH activities
on the onset of labor, pregnant mice were treated daily with a
CRH type I receptor selective antagonist Antalarmin hydrochlo-
ride at a dose of 25 mg/Kg?BW via subcutaneous injections on
days 15–17. Pregnant wild-type mice treated with corticosterone at
a dose of 40 mg/Kg?BW via subcutaneous injections on days 14–
18 were examined to see the effects of enhanced corticosterone
activity on parturition events. While SR141716 and SR144528
were obtained from National Institute on Drug Abuse, Antalarmin
hydrochloride and corticosterone were obtained from Sigma.
Drugs were dissolved in Triolein/ethanol (4:1). Gestation length
was measured by monitoring the parturition status on days 19–21.
In situ hybridization
In situ hybridization of Cnr1 in the brain was performed as
previously described [58]. Briefly, frozen sections (10 mm) were
mounted onto poly-L-lysine-coated slides and fixed in 4%
paraformaldehyde solution in PBS at 4uC. After prehybridization,
sections were hybridized at 45uC for 4 h in 50% formamide buffer
containing
35S-labeled sense or antisense cRNA probes. After
hybridization, sections were incubated with RNase A (20 mg/ml)
at 37uC for 20 min, and RNase A-resistant hybrids were detected
by autoradiography using Kodak NTB-2 liquid emulsion. Sections
were poststained with hematoxylin and eosin. Sections hybridized
with a sense probe did not show any positive signals and served as
controls.
Immunohistochemistry
Immunolocalization of CB1 in the pituitary, ovary and uterus
were performed in formalin-fixed paraffin embedded sections
using specific antibodies to CB1 receptor (Santa Cruz). A
Histostain-Plus (DAB) kit (Invitrogen) was used to visualize the
antigen.
Assay P4,E 2, corticosterone and CRH
Blood samples from WT and Cnr1
2/2mice were collected on
days 14–21 of pregnancy. Serum was separated by centrifugation
(3,000 rpm for 15 min) and stored at 280uC until assayed. P4,E 2,
corticosterone levels were measured by radioimmunoassay by the
UVA Center for Research in Reproduction Ligand Assay and
Analysis Core. CRH was analyzed using an Enzyme Immuno
Assay (EIA) kit purchased from Phoenix Pharmaceuticals INC
following the manufacture’s protocol.
Statistical analyses
Data are expressed as means6s.e.m. Statistical comparisons
between two experimental groups were determined by Student’s t-
test. A P value of less than 0.05 is considered significantly different.
Supporting Information
Figure S1 Inter-crossing of Cnr12/2 females with wild-type
(WT) males fails to correct preterm labor phenotype in Cnr12/2
females bearing heterozygous embryos (A), although fetal weights
of heterozygous embryos were comparable to those of WT at birth
(B). Data are means6SEM. Numbers within bars in panel (A)
indicate the number of mice examined. The average fetal weights
(mg) are shown in panel B. The bars with different letters are
significantly different (Student t-test, P,0.01).
Found at: doi:10.1371/journal.pone.0003320.s001 (1.35 MB TIF)
Figure S2 A single subcutaneous injection of progesterone (P4,
1 mg/mouse) on day 18 of pregnancy restores normal parturition
(A) and fetal development at term (B) in Cnr12/2 mice. Mice
receiving the same volume of sesame oil served as controls. Data
are means6SEM. Numbers within bars in panel (A) indicate the
number of mice examined. The average fetal weights (mg) are
shown in panel B. The bars with different letters are significantly
different (Student t-test, P,0.01).
Found at: doi:10.1371/journal.pone.0003320.s002 (2.62 MB TIF)
Figure S3 Immunolocalization of CRH and CRH-RI in WT
pregnant day 18 ovaries. Bar, 100 mm. CL, corpus luteum; f,
follicle; Hip: hippocampus; o, oocyte.
Found at: doi:10.1371/journal.pone.0003320.s003 (3.44 MB TIF)
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